Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Jiandong Lu, Kevin Horgan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands, Jean Frédéric Colombel

Research output: Contribution to journalArticlepeer-review

439 Scopus citations

Abstract

Background & Aims: The efficacy of infliximab for treating patients with ulcerative colitis has been established. Methods: The Active Ulcerative Colitis Trial (ACT)-1 and ACT-2 randomized, double-blind, placebo-controlled studies evaluated infliximab induction and maintenance therapy in moderately to severely active ulcerative colitis. Overall, 728 patients received placebo or infliximab (5 or 10 mg/kg) intravenously at weeks 0, 2, and 6, then every 8 weeks through week 46 (ACT-1) or 22 (ACT-2). Colectomy, hospitalization, and surgery/procedure data through 54 weeks after the first infusion were obtained from ACT-1, ACT-2, and associated data sources. In the prespecified analysis, all data were combined to ascertain time to colectomy. Kaplan-Meier product-limit method was used to estimate the cumulative incidence of colectomy, and log-rank test was used to compare the combined infliximab group and placebo. Results: Eighty-seven percent (630 of 728) of patients had complete colectomy follow-up; 13% (98 of 728) of patients had a median follow-up of 6.2 months. The cumulative incidence of colectomy through 54 weeks was 10% for infliximab and 17% for placebo (P = .02), yielding an absolute risk reduction of 7%. Compared with placebo, fewer ulcerative colitis-related hospitalizations and surgeries/procedures per 100 patient-years of treatment occurred with infliximab therapy: 40 vs 20 (P = .003) and 34 vs 21 (P = .03), respectively. Serious adverse events occurring in infliximab-treated patients included serious infections, tuberculosis, histoplasmosis, listeriosis, and malignancy. Conclusions: Patients with moderately to severely active ulcerative colitis treated with infliximab were less likely to undergo colectomy through 54 weeks than those receiving placebo.

Original languageEnglish
Pages (from-to)1250-1260
Number of pages11
JournalGastroenterology
Volume137
Issue number4
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab'. Together they form a unique fingerprint.

Cite this